DrugPatentWatch Database Preview
Daratumumab - Biologic Drug Details
» See Plans and Pricing
Summary for daratumumab
Tradenames: | 1 |
Patents: | 20 |
Applicants: | 1 |
BLAs: | 1 |
Suppliers: see list | 1 |
Recent Clinical Trials: | See clinical trials for daratumumab |
Recent Clinical Trials for daratumumab
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Janssen-Cilag G.m.b.H | Phase 2 |
University of Cologne | Phase 2 |
Oncopeptides AB | Phase 3 |
Pharmacology for daratumumab
Ingredient-type | Antibodies, Monoclonal |
Mechanism of Action | CD38-directed Antibody Interactions |
Patent Text Search: US Patents for daratumumab
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | DARZALEX | daratumumab | INJECTABLE;INJECTION | 761036 | 001 | 2015-11-16 | Start Trial | Excelse Bio, Inc. (Thousand Oaks, CA) | 2031-10-28 | RX | Orphan | search |
Janssen Biotech | DARZALEX | daratumumab | INJECTABLE;INJECTION | 761036 | 001 | 2015-11-16 | Start Trial | ABBVIE STEMCENTRX LLC (North Chicago, IL) | 2032-02-08 | RX | Orphan | search |
Janssen Biotech | DARZALEX | daratumumab | INJECTABLE;INJECTION | 761036 | 001 | 2015-11-16 | Start Trial | AbbVie Stemcentrx LLC (North Chicago, IL) | 2033-02-08 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for daratumumab
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 255884 | Start Trial |
Japan | 2018506293 | Start Trial |
Mexico | 2016016617 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |